BioSpecifics Technologies Corp (NASDAQ:BSTC) on Monday reported a merger agreement with Endo International plc (NASDAQ:ENDP) for an estimated equity value of USD658.0m and USD540.0m in enterprise value net of cash on hand or USD88.50 per share in cash.
Through a wholly-owned subsidiary, Endo will commence an all-cash tender offer for all outstanding shares of BioSpecifics common stock at a price of USD88.50 per share.
The transaction is anticipated to close during the fourth quarter of 2020, subject to a number of conditions, including that a majority of BioSpecifics' shares are tendered in the tender offer, the expiration of the waiting period under antitrust laws and other customary closing conditions.
Upon completion of the tender offer, Endo's acquisition subsidiary will be merged into BioSpecifics, with any remaining shares of BioSpecifics common stock to be canceled and converted into the right to receive consideration of USD88.50.
BioSpecifics Technologies Corp. is a commercial-stage biopharmaceutical company. It has discovered and developed a proprietary form of injectable collagenase (CCH), which is currently marketed as XIAFLEX in North America for the treatment of Dupuytren's contracture and Peyronie's disease. It has received FDA approval of CCH for the treatment of moderate to severe cellulite in the buttocks of adult women; The R*D pipeline includes several additional potential indications including adhesive capsulitis and plantar fibromatosis.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial